| Revenue growth | 62% YoY growth driven by US regulated markets expansion. |
|---|---|
| Margins | EBITDA margins improved to 30%, up 526 bps YoY. |
| Demand visibility | Strong visibility with 51 approved ANDAs and 27 molecules in pipeline. |
| Management confidence | Extremely high; aggressive guidance for FY27 reflecting strong execution. |
Growth
Revenue grew 62% and PAT 108% YoY, primarily driven by 51 approved ANDAs and niche molecule focus.
Outlook
FY27 guidance: Revenue growth of 30-40% and PAT growth of 50-60%.
Risks
High reliance on 'Other Financial Assets' for profit sharing; logistical costs and US inflationary pressures persist.
Earnings Call filed with NSE, NSE: SENORES. Summary written with AI assistance from the document.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,355.20
- Market cap
- ₹6,241 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 49.4×Sector 50.4×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals Price Movement Clarification
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).
Senores Pharmaceuticals Business Update
Senores Pharma's subsidiary Apnar Pharma completed a USFDA inspection at its Vadodara facility with no GMP observations. Only one minor procedural finding was noted.
Senores Pharmaceuticals Annual Report
Senores Pharmaceuticals issued a corrigendum to its FY 2025-26 Annual Report to rectify typographical errors in the narrative and Director's Report sections. The original report remains valid.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Ltd submitted its Annual Report for FY 2025-26 and notice for its 9th Annual General Meeting scheduled for September 25, 2026.